Search

Corcept Therapeutics Inc

Chiusa

SettoreSettore sanitario

114.85 0.65

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

108.28

Massimo

116.61

Metriche Chiave

By Trading Economics

Entrata

75M

43M

Vendite

91M

256M

P/E

Media del settore

248.445

56.432

EPS

0.36

Margine di Profitto

16.782

Dipendenti

730

EBITDA

91M

47M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+23.95% upside

Dividendi

By Acuity

Utili prossimi

3 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.3B

12B

Apertura precedente

114.2

Chiusura precedente

114.85

Notizie sul Sentiment di mercato

By Acuity

13%

87%

8 / 339 Classifica in Healthcare

Corcept Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 set 2026, 20:06 UTC

Corcept Therapeutics Inc is advancing, maintaining significant gains since Friday's close, despite earlier pulling back from a session high.

18 set 2026, 20:02 UTC

Social Media
News

Shares of Corcept Therapeutics fell sharply despite a positive CHMP opinion on relacorilant for ovarian cancer and a reiterated Buy rating from HC Wainwright.

17 set 2026, 20:01 UTC

News

Corcept Therapeutics shares are rising, supported by record revenue and net income growth for Q2 2026, along with an increased revenue guidance of up to $1.2 billion.

15 set 2026, 20:07 UTC

Corcept Therapeutics Inc is trading lower amid a broader market decline, influenced by a significant drop in the NY Empire State Manufacturing Index.

14 set 2026, 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid broader market concerns over rising crude oil prices and inflation ahead of the Federal Reserve's interest rate decision.

11 set 2026, 20:08 UTC

Corcept Therapeutics Inc shares are lower today, reflecting broader market trends amid volatility and recent inflation data showing a monthly increase of 0.4%.

10 set 2026, 19:21 UTC

Corcept Therapeutics Inc shares are lower amid broader market declines and rising Treasury yields, with no specific company news identified.

8 set 2026, 20:07 UTC

Corcept Therapeutics Inc shares are higher today, recovering from an early decline. The stock peaked midday but remains below the 20-day moving average.

2 set 2026, 20:08 UTC

Corcept Therapeutics Inc. shares are lower today, breaking a recent trend of gains. The broader market is impacted by a weak ADP employment report.

1 set 2026, 20:08 UTC

Corcept Therapeutics Inc shares are lower amid broader market declines driven by rising oil prices and increasing inflation concerns ahead of the Federal Reserve meeting.

28 ago 2026, 20:01 UTC

Corcept Therapeutics Inc shares are lower, continuing a four-day decline amid notable volatility and unusually high market volume. No specific news was identified.

27 ago 2026, 23:42 UTC

Corcept Therapeutics Inc is higher in after-market trading, recovering from earlier lows. Economic data showing a decline in jobless claims may support market sentiment.

26 ago 2026, 19:51 UTC

Corcept Therapeutics Inc shares are lower today, reaching a session low and marking a decline since Tuesday's close, with high trading volume noted.

25 ago 2026, 23:06 UTC

Corcept Therapeutics Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid falling crude oil prices and easing geopolitical concerns.

24 ago 2026, 19:36 UTC

News

Corcept Therapeutics shares are lower despite Zacks raising Q3 2026 EPS estimate to $0.34. The company reported Q2 earnings of $0.36 per share.

21 ago 2026, 20:01 UTC

News

Corcept Therapeutics Inc is higher today, supported by strong sector performance and increased trading volume amid a positive growth outlook and upcoming FDA decision on Relacorilant.

20 ago 2026, 23:41 UTC

Corcept Therapeutics Inc. shares are trading roughly flat in after-market hours. The asset remains above its 20-day moving average.

13 ago 2026, 19:46 UTC

Corcept Therapeutics Inc is declining today, with no specific news identified. The stock peaked earlier but has since retraced from that high.

12 ago 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today amid a positive trend in U.S. stocks, despite geopolitical tensions and rising crude oil prices.

11 ago 2026, 20:06 UTC

Corcept Therapeutics Inc. shares are lower today, having declined steadily after reaching a session high earlier. The stock remains above its 20-day moving average.

10 ago 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today, recovering from an early drop despite a broader market decline amid labor market concerns.

7 ago 2026, 21:01 UTC

Corcept Therapeutics Inc shares are lower in after-market trading, declining despite being above its 20-day moving average and near the upper end of its one-month range.

5 ago 2026, 19:56 UTC

Corcept Therapeutics Inc's shares are higher today, reflecting a generally positive market environment. The stock remains significantly above its 20-day moving average.

4 ago 2026, 19:16 UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

3 ago 2026, 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

31 lug 2026, 22:26 UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

30 lug 2026, 23:11 UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

29 lug 2026, 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

28 lug 2026, 19:46 UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

27 lug 2026, 23:46 UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

Confronto tra pari

Modifica del prezzo

Corcept Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

23.95% in crescita

Previsioni per 12 mesi

Media 141 USD  23.95%

Alto 165 USD

Basso 50 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Corcept Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

4

Acquista

0

Mantieni

1

Vendi

Sentiment

By Acuity

8 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.